FGEN FibroGen Inc

57.32
-1.18  -2%
Previous Close 58.5
Open 58.38
Price To Book 10.33
Market Cap 4870942170
Shares 84,978,056
Volume 162,950
Short Ratio
Av. Daily Volume 694,882

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pooled MACE safety data 1H 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 2 initial data due late 1Q 2019.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 3 trial to commence 2019.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 3 trial to be initiated 1Q 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 3 Japan data noted hepcidin reduction from baseline (p=0.003) compared to epoetin alfa group (p=0.12)
Roxadustat
Chronic kidney disease

Latest News

  1. See what the IHS Markit Score report has to say about FibroGen Inc.
  2. How Much is FibroGen, Inc.’s (NASDAQ:FGEN) CEO Getting Paid?
  3. Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and FibroGen
  4. Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results
  5. Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes
  6. [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time
  7. AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment
  8. FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
  9. Today's Research Reports on Trending Tickers: Aimmune Therapeutics and FibroGen
  10. FibroGen Inc (FGEN): Hedge Fund Sentiment Unchanged
  11. Why a kidney disease drug approval in China is just the start for this S.F. company
  12. The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
  13. Today's Research Reports on Trending Tickers: Puma Biotechnology and FibroGen
  14. China first to approve AstraZeneca, FibroGen anaemia drug
  15. FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
  16. How Many Insiders Sold FibroGen, Inc. (NASDAQ:FGEN) Shares?